TRVI
Trevi Therapeutics Inc
$
7.600
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.650
Open
7.285
VWAP
7.50
Vol
832.38K
Mkt Cap
892.62M
Low
7.285
Amount
6.24M
EV/EBITDA(TTM)
--
Total Shares
70.44M
EV
688.74M
EV/OCF(TTM)
--
P/S(TTM)
--
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-0.123
+37.03%
--
--
-0.114
+3.41%
--
--
-0.101
-22.12%
Estimates Revision
The market is revising No Change the revenue expectations for Trevi Therapeutics, Inc. (TRVI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 17.74%.
EPS Estimates for FY2025
Revise Downward
-0.27%
In Past 3 Month
Stock Price
Go Up
+17.74%
In Past 3 Month
9 Analyst Rating
185.13% Upside
Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 21.67 USD with a low forecast of 13.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
185.13% Upside
Current: 7.600
Low
13.00
Averages
21.67
High
29.00
185.13% Upside
Current: 7.600
Low
13.00
Averages
21.67
High
29.00
Raymond James
Strong Buy
downgrade
$29 -> $27
2025-08-08
New
Reason
Raymond James
Price Target
$29 -> $27
2025-08-08
New
downgrade
Strong Buy
Reason
Raymond James lowered the firm's price target on Trevi Therapeutics to $27 from $29 and keeps a Strong Buy rating on the shares. The firm believes Haduvio is the most efficacious treatment in clinical development for both IPF-chronic cough and refractory chronic cough, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
initiated
$25
2025-07-01
Reason
Cantor Fitzgerald
Price Target
$25
2025-07-01
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Trevi Therapeutics with an Overweight rating and $25 price target.
Cantor Fitzgerald
Overweight
initiated
$25
2025-07-01
Reason
Cantor Fitzgerald
Price Target
$25
2025-07-01
initiated
Overweight
Reason
Cantor Fitzgerald initiated coverage of Trevi Therapeutics with an Overweight rating and $25 price target. Cantor tells investors in a research note that "this is about as high conviction a call as we'll ever have" for a pre-commercial program. Trevi's Haduvio, a mixed opioid agonist/antagonist in development for chronic cough, has shown a very consistent and very strong reduction in cough across multiple Phase 2 studies in interstitial pulmonary fibrosis and refractory chronic cough and is the first and only drug to show positive data in both IPF and RCC, the firm says.
Oppenheimer
Oppenheimer
Outperform
maintain
$20 -> $23
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$20 -> $23
2025-06-02
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Trevi Therapeutics to $23 from $20 and keeps an Outperform rating on the shares. The company's positive topline Phase 2b announcement builds a strong case for Haduvio to broadly address idiopathic pulmonary fibrosis chronic cough, in which no options are approved and candidates elsewhere have disappointed, the analyst tells investors in a research note. The firm says the placebo-like discontinuation rate across the active arms should resolve a key investor concern. Today's selloff "reflects small-cap biotech trading dynamics that have become all too familiar in the current market environment," contends Oppenheimer.
H.C. Wainwright
H.C. Wainwright
initiated
$21
2025-05-28
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$21
2025-05-28
initiated
Reason
H.C. Wainwright initiated coverage of Trevi Therapeutics with a Buy rating and $21 price target. The company is developing Haduvio for both refractory chronic cough and idiopathic pulmonary fibrosis chronic cough, the analyst tells investors in a research note. The firm views Trevi 's RIVER Phase 2a data in refractory chronic cough, released earlier this year, as compelling, and believes the company now has a "meaningfully more derisked path" to approval in RCC than the market gives it credit for.
Needham
Serge Belanger
Strong Buy
Reiterates
$24
2025-04-08
Reason
Needham
Serge Belanger
Price Target
$24
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Trevi Therapeutics Inc (TRVI.O) is -15.75, compared to its 5-year average forward P/E of -5.18. For a more detailed relative valuation and DCF analysis to assess Trevi Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.18
Current PE
-15.75
Overvalued PE
-1.55
Undervalued PE
-8.82
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.85
Current EV/EBITDA
-10.46
Overvalued EV/EBITDA
0.65
Undervalued EV/EBITDA
-4.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
YoY :
+3.26%
-13.72M
Operating Profit
FY2025Q2
YoY :
-0.41%
-12.30M
Net Income after Tax
FY2025Q2
YoY :
-25.00%
-0.09
EPS - Diluted
FY2025Q2
YoY :
+15.96%
-10.10M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 218.66% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
600.9K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
188.6K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.2M
Volume
3
6-9
Months
4.5M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
745.6K
Volume
Months
6-9
2
5.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 218.66% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
600.9K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
188.6K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TRVI News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
16:16:39
Trevi Therapeutics reports Q2 EPS (9c), consensus (10c)
2025-06-04 (ET)
2025-06-04
06:04:29
Trevi Therapeutics 17.4M share Secondary priced at $5.75
2025-06-02 (ET)
2025-06-02
16:02:11
Trevi Therapeutics announces $100M common stock offering
Sign Up For More Events
Sign Up For More Events
News
9.5
08-07PRnewswireTrevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
9.5
07-31PRnewswireTrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
1.0
07-29NewsfilterTrevi Therapeutics to Participate in Upcoming August Conferences
Sign Up For More News
People Also Watch
CVEO
Civeo Corp
22.450
USD
-0.71%
ZBIO
Zenas Biopharma Inc
16.440
USD
+3.40%
NETD
Nabors Energy Transition Corp II
11.260
USD
0.00%
CANG
Cango Inc
4.854
USD
-2.33%
MBX
MBX Biosciences Inc
14.075
USD
+12.33%
BRT
BRT Apartments Corp
15.220
USD
+0.79%
CIX
CompX International Inc
31.800
USD
+5.79%
LPA
Logistic Properties of The Americas
6.410
USD
-1.08%
CIVB
Civista Bancshares Inc
20.690
USD
+0.98%
HBANL
Huntington Bancshares Inc
25.630
USD
+0.43%
FAQ
What is Trevi Therapeutics Inc (TRVI) stock price today?
The current price of TRVI is 7.6 USD — it has increased 3.68 % in the last trading day.
What is Trevi Therapeutics Inc (TRVI)'s business?
What is the price predicton of TRVI Stock?
What is Trevi Therapeutics Inc (TRVI)'s revenue for the last quarter?
What is Trevi Therapeutics Inc (TRVI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Trevi Therapeutics Inc (TRVI)'s fundamentals?
How many employees does Trevi Therapeutics Inc (TRVI). have?